Loading
A phase 3 trial of adebrelimab, cisplatin, carboplatin, pemetrexed and other drugs in lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., not yet recruiting.
A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07822542 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with a registry enrolment figure of 448 participants, started 2026-10-31 and due to reach its primary completion in 2030-05-31. Interventions recorded: HS-10370; Adebrelimab; Cisplatin; Carboplatin; Pemetrexed; Tislelizumab. Conditions listed: Carcinoma, Non-Small-Cell Lung. Primary outcome: Progression-Free Survival (PFS). Lung eligibility wording from the registry: "* Interstitial lung disease (ILD)". No results are recorded here; the registry entry is the source.
Shares Tislelizumab, Pemetrexed, Lung cancer trials open today (registry snapshot), Cisplatin and the tag lung-deep-dive.
Shares Tislelizumab, KRAS G12C-mutant non-small-cell lung cancer, Pemetrexed, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Tislelizumab, Pemetrexed, Lung cancer trials open today (registry snapshot), Cisplatin and the tag lung-deep-dive.
Shares Tislelizumab, Pemetrexed, Lung cancer trials open today (registry snapshot), Cisplatin and the tag lung-deep-dive.
Shares Hansoh Pharmaceutical, Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents and the tag lung-deep-dive.
Shares Tislelizumab, Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents and the tag lung-deep-dive.